Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,281.0
3.0 (0.09%)

 

  • STI Straits Times Index
    3,281.0
    3.0 (0.09%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,595.8
    7.9 (0.50%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    29,056.4
    173.4 (0.60%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,075.5
    1.4 (0.05%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    24,041.3
    108.1 (0.45%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,291.7
    5.6 (0.09%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,250.6
    2.5 (0.11%)
    Index delayed 20 minutes
  • XAO XAO
    7,180.3
    21.7 (0.30%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,723.5M
  • Value: 1,021.1M
  • Rise: 204
  • Fall: 116
  • Unch: 499

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
AsiaPhos0.047+0.019
Golden Agri-Res0.235-
OEL0.029+0.009
Sincap0.013+0.003
Rex Intl0.192+0.011
AusGroup^0.048+0.001
BlackGoldNatural0.018+0.002
AsiaMedic0.013+0.002
Ley Choon0.022+0.004
GCCP0.009+0.002

World Indices

World Indices
Name Last Change
Nasdaq 9,388.9 +31.8
HSI 29,056.4 +173.4
HSCEI 11,419.9 +91.5
Jakarta 6,291.7 +5.6
Nikkei 225 24,041.3 +108.1
SSE Comp 3,075.5 +1.4
Shanghai A 3,222.5 +1.4
Shanghai B 260.1 +2.0
PSE Comp 0.0
KOSPI 2,250.6 +2.5

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

ALPHAMAB-B ALPHAMAB-B
Quotes 15 Minutes Delayed. Updated at 17 Jan 2020 16:08
Last (HKD): 14.660 Change: +0.280 High: 14.660 Remarks: -
Change (%): +1.95 Low: 14.200
Open 14.400 Yesterday's Close 14.380
Buy Price 14.600 Sell Price 14.640
Buy Volume ('000) 14 Sell Volume ('000) 4
Cumulative Volume ('000) 855 Cumulative Value 12,323,240
 
Click to show Stock Prices chart

Key Statistics

EPS (HKD) a - Trailing EPS (HKD) e - NAV (HKD) b -0.3857
PE a - Trailing PE f - Price / NAV b -38.0088
Dividend (HKD) d - Cash In Hand (HKD) g 0.3122 Issued & Paid-up Shares c 923,922,000
Dividend Yield (%) d - Price / Cash In Hand g 46.957 Treasury Shares h -
Beta - 75 Daysi 3.209 R-Squared - 75 Days(%)i 11.56 Market Cap (M) 13,544.697
Beta - 500 Daysi 2.867 R-Squared - 500 Days (%)i 12.67 Enterprise Value (M) 14,177.092
Piotroski F Score - Exchange Code 9966 Par Value ( USD ) n.a.
52 Weeks Volatility (%) n.a. 6-Month VWAP n.a. Free Float (%) 48.2
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 09 Jan 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 05 Dec 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ALPHAMAB-B HKEx 13,544.697 - - -38.0088 -
Industry Biotechnology HKEx 48,727.640 14.992 16.012 6.4133 2.437
Local Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Local Peer SINO BIOPHARM HKEx 147,105.276 13.729 14.249 4.3809 0.626
Local Peer WUXI BIO HKEx 135,974.714 182.049 142.322 13.9969 -
Local Peer BEIGENE HKEx 102,874.590 - - 10.2644 -
Local Peer GENSCRIPT BIO HKEx 35,347.948 212.573 - 9.9682 -
Local Peer 3SBIO HKEx 28,549.263 18.872 22.971 2.8139 -
Local Peer HAOHAI BIOTEC HKEx 13,909.376 28.328 31.396 3.2749 0.748
Local Peer FRONTAGE HKEx 9,696.901 110.073 110.065 5.0187 -
Local Peer CKLIFE SCIENCES HKEx 8,361.631 31.798 31.754 2.0028 1.149
Local Peer VIVA BIOTECH HKEx 7,324.936 68.298 68.296 3.8028 -
Local Peer ASCENTAGE-B HKEx 5,983.450 - - -3.2401 -
Local Peer SINOMAB BIO-B HKEx 4,326.832 - - - -
Other Local Peers ESSEX BIO-TECH (HKEx), ASCLETIS-B (HKEx), LEE'S PHARM (HKEx), BBI LIFE SCI (HKEx), UNI-BIO GROUP (HKEx), CT ENTERPRISE (HKEx), BIOSINO BIO-TEC (HKEx), REGENT PACIFIC (HKEx), EXTRAWELL PHAR (HKEx), HAO WEN HLDGS (HKEx)
Global Peer AMGEN INC NASDAQ 143,489.494 17.094 17.787 13.1317 2.317
Global Peer CSL ASX 136,206.687 50.768 50.768 18.2018 0.884
Global Peer GILEAD SCIENCES INC NASDAQ 79,679.147 14.607 29.588 3.8672 3.668
Global Peer VERTEX PHARMACEUTICAL NASDAQ 60,643.685 28.928 28.288 11.5437 -
Global Peer BIOGEN INC NASDAQ 51,516.191 11.627 9.548 3.6808 -
Global Peer ILLUMINA INC NASDAQ 47,733.840 57.789 49.058 10.7533 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 42,374.657 17.335 19.762 4.0340 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,953.692 88.461 26.101 5.8875 0.678
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,065.632 323.010 17.048 2.4178 -
Global Peer SEATTLE GENETICS INC NASDAQ 18,681.074 - - 10.4973 -
Other Global Peers INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), REPLIGEN CORP (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), Lonza (SGX), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), FIBROGEN INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), NATERA INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), UNIQURE N.V. (NASDAQ), KODIAK SCIENCES INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), VIELA BIO INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), EPIZYME INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), XENCOR INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), ARVINAS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), NEXTCURE INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), TG THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), ALECTOR INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), NGM BIOPHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), POLYNOVO LIMITED (ASX), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), AVITA MEDICAL LTD (ASX), LUMINEX CORP(DEL) (NASDAQ), OPKO HEALTH INC (NASDAQ), XBIOTECH INC (NASDAQ), DERMIRA INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), ACHILLION PHARMACEUTICALS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), OMEROS CORP (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), CYTOKINETICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), IMMUNOGEN INC (NASDAQ), RETROPHIN INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), KADMON HLDGS INC (NYSE), REPLIMUNE GROUP INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), ARDELYX INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MACROGENICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), MERUS B V (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), BELLUS HEALTH INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PERSONALIS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), COMPUGEN (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), IVERIC BIO INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), VBI VACCINES INC CDA (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), MEDICINOVA INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), PFENEX INC (NYSE American), GERON CORP (NASDAQ), NEXT SCIENCE LTD (ASX), WAVE LIFE SCIENCES LTD (NASDAQ), DPHARMA (Bursa), ADMA BIOLOGICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), KAMADA (NASDAQ), TELIX PHARMACEUTIC (ASX), LIMINAL BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), SYNDAX PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), CHIASMA INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), XOMA CORP (NASDAQ), NANOVIRICIDES INC (NYSE American), IMV INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), ATHERSYS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), ARAVIVE INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), CONTRAFECT CORP (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), SAVARA INC (NASDAQ), NOVAVAX INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), VERASTEM INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), RESAPP HEALTH LIMITED (ASX), CYMABAY THERAPEUTICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ENZO BIOCHEM INC (NYSE), PYC THERAPEUTICS LIMITED (ASX), CHIMERIX INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), CIDARA THERAPEUTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), 22ND CENTURY GROUP INC (NYSE American), AXCELLA HEALTH INC (NASDAQ), PALATIN TECHNOLOGIES INC (NYSE American), IMUGENE LIMITED (ASX), OTONOMY INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ADURO BIOTECH INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), SESEN BIO INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SYNLOGIC INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), COHBAR INC (NASDAQ), CEL-SCI CORP (NYSE American), CYNATA THERAPEUTICS LTD (ASX), CATALYST BIOSCIENCES INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), TREVENA INC (NASDAQ), IMMUTEP LTD (ASX), ORGENESIS INC (NASDAQ), VERMILLION INC (NASDAQ), EQUILLIUM INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), ORTHOCELL LIMITED (ASX), KEZAR LIFE SCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), INMUNE BIO INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ZAFGEN INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), ISORAY INC (NYSE American), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), EVOGENE LTD (NASDAQ), SOLIGENIX INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), OCUGEN INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), ANTEOTECH LIMITED (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), APTEVO THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), BIOTRON (ASX), UNUM THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), GENETIC TECHNOLOGIES (ASX), ATYR PHARMA INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), TALI DIGITAL LIMITED (ASX), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), ORAGENICS INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), SOPHIRIS BIO INC (NASDAQ), IBIO INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), MIRAGEN THERAPEUTICS INC (NASDAQ), RHINOMED LIMITED (ASX), BIO-PATH HOLDINGS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CCP TECHNOLOGIES LTD (ASX), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), VAXART INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CELLMID LIMITED (ASX), SENESTECH INC (NASDAQ), IMMURON LIMITED (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), PRECIPIO INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), PATRYS LIMITED (ASX), REGENEUS LTD (ASX), BIOCEPT INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), CONATUS PHARMACEUTICALS INC (NASDAQ), TOCAGEN INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ADALTA LTD (ASX), HEAT BIOLOGICS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), TROVAGENE INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), CLEVELAND BIOLABS INC (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), OPGEN INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), BIOXYNE LIMITED (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), MEDIBIO LIMITED (ASX), LIVING CELL TECHNOLOGIES (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), AIM IMMUNOTECH INC (NYSE American), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), QT Vascular (SGX), MGRC (Bursa), SENECA BIOPHARMA INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), TBG DIAGNOSTICS LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+1.300
+9.73 %
10 Days -+0.860
+6.23 %
20 Days -+0.660
+4.71 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 13.000 - 15.340 Change From 1 Year Low +1.660 % Change From 1 Year Low (%) +12.77
Change From 1 Year High -0.680 % Change From 1 Year High (%) -4.43
2 Years Range 13.000 - 15.340 Change From 2 Years Low +1.660 % Change From 2 Years Low (%) +12.77
Change From 2 Years High -0.680 % Change From 2 Years High (%) -4.43
5 Years Range 13.000 - 15.340 Change From 5 Years Low +1.660 % Change From 5 Years Low (%) +12.77
Change From 5 Years High -0.680 % Change From 5 Years High (%) -4.43
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Alphamab Oncology is an investment holding company. It engages in the research and development, manufacturing and commercialization of biologics of oncology through its subsidiaries. The company was founded by Xu Ting in Novemeber 2008 and is headquartered in Suzhou, China.

Historical Price Data

Date Open High Low Close Volume VWAP
17 Jan 2020 14.400 14.660 14.200 14.660 855,000 14.4131
16 Jan 2020 13.520 14.600 13.520 14.380 2,629,000 14.1450
15 Jan 2020 13.200 13.580 13.200 13.440 1,682,000 13.4254
14 Jan 2020 13.060 13.600 13.060 13.360 1,481,000 13.2471
13 Jan 2020 13.360 13.440 13.000 13.060 1,484,000 13.0837
10 Jan 2020 13.400 14.100 13.280 13.360 2,903,000 13.4024
09 Jan 2020 13.340 13.600 13.240 13.300 1,159,000 13.3389
08 Jan 2020 13.420 13.540 13.140 13.200 1,140,000 13.3266
07 Jan 2020 13.500 13.660 13.260 13.420 1,002,000 13.4072
06 Jan 2020 13.800 13.800 13.300 13.540 763,000 13.4745
03 Jan 2020 14.020 14.020 13.740 13.800 2,106,000 13.8125
02 Jan 2020 14.040 14.200 14.000 14.000 3,014,000 14.0085
31 Dec 2019 14.460 14.460 14.000 14.000 295,000 14.1145
30 Dec 2019 14.040 14.740 14.040 14.460 1,045,000 14.4053
27 Dec 2019 14.000 14.440 13.900 14.200 878,000 14.0994
24 Dec 2019 14.060 14.060 13.740 14.000 1,250,000 13.8805
23 Dec 2019 14.000 14.200 13.680 14.140 922,500 13.9189
20 Dec 2019 14.220 14.400 13.880 14.000 1,244,000 14.0476
19 Dec 2019 14.000 14.440 13.700 14.440 1,863,000 14.0510
18 Dec 2019 14.600 14.780 13.680 14.000 3,210,000 14.0836
17 Dec 2019 15.300 15.300 14.260 14.680 4,880,000 14.6169
16 Dec 2019 14.220 15.340 14.220 15.100 9,777,000 15.0031
Summary
Current 2 Weeks
(06 Jan 2020 to 17 Jan 2020)		 13.800 14.660 13.000 14.660 15,098,000 -
Previous 2 Weeks
(18 Dec 2019 to 03 Jan 2020)		 14.600 14.780 13.000 13.800 15,827,500 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.